AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Alanine--tRNA ligase, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q5JTZ9

UPID:

SYAM_HUMAN

Alternative names:

Alanyl-tRNA synthetase

Alternative UPACC:

Q5JTZ9; A2RRN5; Q8N198; Q96D02; Q9ULF0

Background:

Alanine--tRNA ligase, mitochondrial, also known as Alanyl-tRNA synthetase, plays a crucial role in protein synthesis. It catalyzes the attachment of alanine to tRNA(Ala), facilitating the accurate translation of genetic information into functional proteins. Additionally, it ensures the fidelity of protein synthesis through its editing domain, which corrects incorrectly charged tRNA(Ala).

Therapeutic significance:

The protein is implicated in Combined oxidative phosphorylation deficiency 8, a mitochondrial disease with severe cardiomyopathy, and in Leukoencephalopathy with ovarian failure, marked by neurodegeneration and premature ovarian failure. Understanding the role of Alanine--tRNA ligase, mitochondrial, could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.